By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd. (HKG: 2493) announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate a clinical trial evaluating its investigational candidate 9MW5211 for the treatment of primary biliary cholangitis (PBC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Product | 9MW5211 |
| Indication | Treatment of primary biliary cholangitis (PBC) |
| Approval Date | 31 Jul 2026 |
| Next Steps | Initiate Phase I/II clinical trial with safety and efficacy evaluation |
Drug Profile & Mechanism of Action
- Molecule: Highly specific depleting innovative antibody
- Target: Pathogenic immune cells overexpressing target protein in autoimmune diseases
- Innovation: Following multiple rounds of molecular engineering optimization, 9MW5211 demonstrates excellent target selectivity, achieving potent blockade while significantly reducing non-specific binding risks to ensure deep depletion of pathogenic cells
- Development Status: In-house developed candidate designed to precisely intervene in key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases
Clinical Development Strategy
Mabwell plans to initiate the Phase I/II clinical trial focusing initially on safety, tolerability, and pharmacokinetic profiles before progressing to PBC patients. The company expects to complete enrollment within 18 months and anticipates preliminary efficacy data by mid-2028.
Primary biliary cholangitis affects approximately 30,000-40,000 individuals in China, with limited treatment options currently available. Ursodeoxycholic acid (UDCA) remains the first-line therapy, but up to 40% of patients demonstrate inadequate response, creating substantial demand for alternative therapeutic approaches.
Market Impact & Outlook
- China PBC Landscape: With significant unmet medical need due to inadequate response to current standard of care, novel targeted therapies represent high-value assets
- Competitive Edge: Unlike broad immunosuppressants, 9MW5211’s highly specific depleting mechanism may offer improved safety profile while maintaining efficacy
- Commercial Potential: The rare autoimmune liver disease market in China is projected to grow steadily as diagnosis rates improve and novel therapeutics become available
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for 9MW5211. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech